These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 36971772)

  • 1. Laboratory perspectives in the development of polygenic risk scores for disease: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Reddi HV; Wand H; Funke B; Zimmermann MT; Lebo MS; Qian E; Shirts BH; Zou YS; Zhang BM; Rose NC; Abu-El-Haija A;
    Genet Med; 2023 May; 25(5):100804. PubMed ID: 36971772
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinical application of polygenic risk scores: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Abu-El-Haija A; Reddi HV; Wand H; Rose NC; Mori M; Qian E; Murray MF;
    Genet Med; 2023 May; 25(5):100803. PubMed ID: 36920474
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical utility of polygenic risk scores for embryo selection: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Grebe TA; Khushf G; Greally JM; Turley P; Foyouzi N; Rabin-Havt S; Berkman BE; Pope K; Vatta M; Kaur S;
    Genet Med; 2024 Apr; 26(4):101052. PubMed ID: 38393332
    [No Abstract]   [Full Text] [Related]  

  • 4. Correspondence on "Clinical utility of polygenic risk scores for embryo selection: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG)" by Grebe et al.
    Widen E; Lello L; Eccles J; Marin D; Treff NR
    Genet Med; 2024 Aug; 26(8):101155. PubMed ID: 38856723
    [No Abstract]   [Full Text] [Related]  

  • 5. Considerations for policymakers for improving health care through telegenetics: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Williams HE; Aiyar L; Dinulos MB; Flannery D; McClure ML; Lloyd-Puryear MA; Sanghavi K; Trotter TL; Viskochil D;
    Genet Med; 2022 Nov; 24(11):2211-2219. PubMed ID: 36040445
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk categorization for oversight of laboratory-developed tests for inherited conditions: an updated position statement of the American College of Medical Genetics and Genomics (ACMG).
    South ST; McClure M; Astbury C; Bashford MT; Benkendorf J; Esplin ED; Monaghan KG; Oglesbee D; Sutton VR; Watson MS;
    Genet Med; 2020 Jun; 22(6):983-985. PubMed ID: 32127695
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical, technical, and environmental biases influencing equitable access to clinical genetics/genomics testing: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Matalon DR; Zepeda-Mendoza CJ; Aarabi M; Brown K; Fullerton SM; Kaur S; Quintero-Rivera F; Vatta M;
    Genet Med; 2023 Jun; 25(6):100812. PubMed ID: 37058144
    [No Abstract]   [Full Text] [Related]  

  • 8. Points to consider in the practice of postmortem genetic testing: A statement of the American College of Medical Genetics and Genomics (ACMG).
    Deignan JL; De Castro M; Horner VL; Johnston T; Macaya D; Maleszewski JJ; Reddi HV; Tayeh MK;
    Genet Med; 2023 May; 25(5):100017. PubMed ID: 36799919
    [No Abstract]   [Full Text] [Related]  

  • 9. Direct-to-consumer prenatal testing for multigenic or polygenic disorders: a position statement of the American College of Medical Genetics and Genomics (ACMG).
    ACMG Board of Directors
    Genet Med; 2021 Nov; 23(11):2027-2028. PubMed ID: 34183790
    [No Abstract]   [Full Text] [Related]  

  • 10. Contributions from medical geneticists in clinical trials of genetic therapies: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Peña LDM; Burrage LC; Enns GM; Esplin ED; Harding C; Mendell JR; Niu ZN; Scharfe C; Yu T; Koeberl DD;
    Genet Med; 2023 Jun; 25(6):100831. PubMed ID: 37031408
    [No Abstract]   [Full Text] [Related]  

  • 11. Incidental detection of acquired variants in germline genetic and genomic testing: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Chao EC; Astbury C; Deignan JL; Pronold M; Reddi HV; Weitzel JN;
    Genet Med; 2021 Jul; 23(7):1179-1184. PubMed ID: 33864022
    [No Abstract]   [Full Text] [Related]  

  • 12. Points to consider to avoid unfair discrimination and the misuse of genetic information: A statement of the American College of Medical Genetics and Genomics (ACMG).
    Seaver LH; Khushf G; King NMP; Matalon DR; Sanghavi K; Vatta M; Wees K;
    Genet Med; 2022 Mar; 24(3):512-520. PubMed ID: 35253645
    [No Abstract]   [Full Text] [Related]  

  • 13. Diagnostic testing for uniparental disomy: a points to consider statement from the American College of Medical Genetics and Genomics (ACMG).
    Del Gaudio D; Shinawi M; Astbury C; Tayeh MK; Deak KL; Raca G;
    Genet Med; 2020 Jul; 22(7):1133-1141. PubMed ID: 32296163
    [No Abstract]   [Full Text] [Related]  

  • 14. Points to consider when assessing relationships (or suspecting misattributed relationships) during family-based clinical genomic testing: a statement of the American College of Medical Genetics and Genomics (ACMG).
    Deignan JL; Chao E; Gannon JL; Greely HT; Hagman KDF; Mao R; Topper S;
    Genet Med; 2020 Aug; 22(8):1285-1287. PubMed ID: 32404921
    [No Abstract]   [Full Text] [Related]  

  • 15. Venous thromboembolism laboratory testing (factor V Leiden and factor II c.*97G>A), 2018 update: a technical standard of the American College of Medical Genetics and Genomics (ACMG).
    Zhang S; Taylor AK; Huang X; Luo B; Spector EB; Fang P; Richards CS;
    Genet Med; 2018 Dec; 20(12):1489-1498. PubMed ID: 30297698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMG).
    Murray MF; Giovanni MA; Doyle DL; Harrison SM; Lyon E; Manickam K; Monaghan KG; Rasmussen SA; Scheuner MT; Palomaki GE; Watson MS;
    Genet Med; 2021 Jun; 23(6):989-995. PubMed ID: 33727704
    [No Abstract]   [Full Text] [Related]  

  • 17. DNA-based screening and personal health: a points to consider statement for individuals and health-care providers from the American College of Medical Genetics and Genomics (ACMG).
    Bean LJH; Scheuner MT; Murray MF; Biesecker LG; Green RC; Monaghan KG; Palomaki GE; Sharp RR; Trotter TL; Watson MS; Powell CM;
    Genet Med; 2021 Jun; 23(6):979-988. PubMed ID: 33790423
    [No Abstract]   [Full Text] [Related]  

  • 18. The interface of genomic information with the electronic health record: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG).
    Grebe TA; Khushf G; Chen M; Bailey D; Brenman LM; Williams MS; Seaver LH;
    Genet Med; 2020 Sep; 22(9):1431-1436. PubMed ID: 32475985
    [No Abstract]   [Full Text] [Related]  

  • 19. Patient re-contact after revision of genomic test results: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG).
    David KL; Best RG; Brenman LM; Bush L; Deignan JL; Flannery D; Hoffman JD; Holm I; Miller DT; O'Leary J; Pyeritz RE;
    Genet Med; 2019 Apr; 21(4):769-771. PubMed ID: 30578420
    [No Abstract]   [Full Text] [Related]  

  • 20. Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG).
    Pal T; Agnese D; Daly M; La Spada A; Litton J; Wick M; Klugman S; Esplin ED; Jarvik GP;
    Genet Med; 2020 Apr; 22(4):681-685. PubMed ID: 31831881
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.